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ABSTRACT 
Background: Preliminary research has reported relationships between three-
dimensional (3D) radiation dose to head and neck structures and consequential 
swallowing/nutritional outcomes. The current study aimed to identify which reported 
dose constraints identified functional impairment at 6 months post-treatment. 
Materials and Methods: Dose constraints with reported relationships to 
swallowing/nutrition were identified through a systematic literature review. Dose 
volume histograms for 12 patients with T1-T3 oropharyngeal cancer treated with 3D 
conformal radiotherapy determined dosages delivered to specific structures. Doses 
were examined in relation to published dose constraints and swallowing/nutritional 
outcomes at 6 months post-treatment. 
Results: Sixty-six percent of the reported mean, maximum and partial doses to eight 
structures correctly identified swallowing and nutrition outcomes at 6 months.   
Discussion: The relationships observed between dosimetric constraints and functional 
outcomes highlight the potential for dosimetric data to assist in prognosis and 
treatment. Systematic research is required to refine dosimetric parameters and the 
impact on outcomes.  
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INTRODUCTION 
The move from 2D radiotherapy planning to 3D planning has allowed more detailed 
reporting of radiation dose in relation to tissue volumes, i.e. the amount of radiation 
provided as a percentage volume to a structure of interest, such as the base of tongue 
(BOT). In the past, maximum point doses were stipulated by normal tissue tolerances 
and these were typically applied only to critical normal tissues, such as the spinal 
cord. In the past 10 years however, there has been a concerted effort to achieve 
greater understanding of the possible relationship between submaximal point dosages 
provided to various other structures, such as those specifically involved in 
swallowing, in an attempt to better understand the consequential impact of radiation 
dose on swallowing, and subsequently nutrition. 
 
Treatment intensification (with altered fractionation radiotherapy, chemotherapy or 
targeted therapy [eg. cetuximab]) for head and neck cancer has been shown to 
improve survival compared with conventional radiotherapy treatment (1-3). These 
approaches however have been associated with increased acute toxicity which has 
resulted negative functional sequelae for both swallowing and nutrition (4). Improved 
treatment delivery with 3D conformal radiotherapy (3DCRT) and intensity modulated 
radiotherapy (IMRT) has allowed intensified treatment to be delivered whilst 
allowing more of the normal tissue to be spared (5), with the potential to  optimize the 
functional outcomes of swallowing and nutrition. Previously, swallowing dysfunction 
has been reported in 30-50% of patients treated with intensive non-surgical regimens 
(6, 7) and has been negatively correlated with quality of life 12 months post-treatment 
(8). Dysphagia has also been associated with anxiety and depression in head and neck 
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cancer survivors (9). Determining which patients will develop swallowing dysfunction 
following non-surgical treatment for head and neck cancer however is challenging.  
Recent evidence has examined the dosimetric parameters of specific swallowing 
organs at risk and their impact on post-treatment dysphagia and nutrition (10-23). Dose 
volume histograms (DVHs) are routinely used in the 3D planning of radiotherapy for 
the assessment and reporting of dose to treatment volumes and OAR, and to ensure 
quality assurance, adequate dose to target structures, and avoidance of dose to nearby 
anatomical structures (24). DVHs can also be generated post-treatment to determine the 
specific radiotherapy mean, maximum and partial doses received by each swallowing 
OAR within the treatment field. Each OAR can have a DVH generated for it, which 
demonstrates the volume of that organ receiving the dose. For example, a V45 of 80% 
to the inferior pharyngeal constrictor (see dashed line DVH in Figure 1) would 
indicate that 80% (Y axis) of the inferior pharyngeal constrictor received a total of 
45Gy (X axis). 
 
It has been hypothesized that the mean, maximum, and partial doses delivered to 
particular swallowing OAR may have a long-term impact on swallowing function, 
and that reduction of dose to these structures may help to minimise dysphagia and 
poor nutrition post-treatment (10-23, 25). Eisbruch et al. (2004) (4) were the first to 
question an association between dose-volume parameters and dysphagia. They 
studied 32 patients with locally advanced head and neck cancer who were treated with 
two chemoradiation protocols associated with high rates of dysphagia and found a 
significant increase in tissue thickness of the pharyngeal constrictors, supraglottic 
larynx, and glottic larynx post-treatment. This enabled these authors to label these 
OAR as “dysphagia/aspiration related structures”, and an initial dose limitation of 
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50Gy to the pharynx was suggested to avoid stricture at this site (4). Subsequent 
studies have utilized the anatomic swallowing OAR and contouring recommendations 
suggested by Eisbruch et al. (2004)(4) to provide further evidence for minimizing 
dysphagia Literature published recently has also indicated relationships between the 
requirement of alternative feeding and dose-volume parameters (21). Investigations of 
additional critical parameters such as nutritional status or percentage weight loss and 
their relation to dose delivered to the swallowing OAR are still yet to be explored. 
 
Enhanced understanding of the relationships between certain radiation dose levels and 
potential negative treatment effects will ultimately lead to informed treatment 
planning, optimisation of patient outcomes and greater prognostic decision making 
regarding patients most at risk for dysphagia and nutritional compromise following 
treatment. However, as yet this area of research is in the early preliminary stages. 
Hence the aims of the current paper are twofold: (1) to critically review the current 
literature and compile the published mean, maximum, and partial dosimetric 
parameters to OAR that have been implicated in swallowing outcomes to date, and (2) 
to examine the radiation dose information of a cohort who received 3D conformal 
AFRT-CB for oropharyngeal cancer with a range of functional outcomes assessed at 6 
months post-treatment. The purpose of this will be to highlight how well the dose 
constraints reported in the literature to date relate to a range of detailed swallowing 
and nutritional outcomes at 6 months post-treatment.  
 
MATERIALS AND METHODS 
Review of the Current Literature 
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Identification of verified dosimetric parameters associated with swallowing and 
nutritional outcomes post-treatment was conducted through a systematic review of the 
literature. Electronic publications in English between January 1990 and May 2011 
were searched for by the first author (BC). CINAHL, Pre-CINAHL, EMBASE, 
Medline and PubMed databases were searched using keywords, subject heading 
words, titles and abstracts. The following Medical Subject Headings (MeSH) search 
terms were used: deglutition, deglutition disorders, intensity modulated radiotherapy, 
radiotherapy and head and neck neoplasms. Additional search terms included 
swallowing, dysphagia, aspiration, videofluoroscopy, dosimetry, dose-volume 
constraints, dose-volume histogram, and head and neck cancer. Studies were included 
if: 1) participants were diagnosed with head and neck cancer; 2) specific swallowing-
related structures were outlined; 3) total, mean, median, maximum, or partial doses of 
radiotherapy to specific swallowing-related structures were reported; 4) “dysphagia 
outcomes” were reported at one or more time points post-treatment and included at 
least one of the following: dysphagia toxicity, aspiration, physiological swallowing 
impairment, stricture, patient-reported swallowing function, diet tolerance, 
swallowing-related or general quality of life, and/or dependence on alternative 
feeding. Studies were excluded if: 1) participants were diagnosed with cancer other 
than that defined to the head and neck area; 2) anatomical structures outlined related 
specifically to outcomes other than swallowing (ie. saliva, skin, voice, edema, 
anatomical change); 3) dysphagia outcome was not reported; 4) radiotherapy dose to 
swallowing-related structures was not reported; or 5) the relationship between the 
dysphagia outcome and radiotherapy dose was not reported. 
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Following this search strategy, the reference lists of identified articles were manually 
searched for additional relevant publications. All relevant publications were reviewed 
by two researchers (BC and RN) and rated for methodological quality based on the 
Transparent Reporting of Evaluations with Non-randomized Designs (TREND) 
checklist, developed to be consistent with the Consolidated Standards or Reporting 
Trials (CONSORT) statement for randomized controlled trials (26). The 22 criteria 
specified by TREND were given a rating of one (satisfies the criteria), or zero (does 
not satisfy the criteria), yielding a possible total quality rating of 22. 
 
A total of 18 studies met the criteria to be included in this review, of which one was a 
systematic review and another of these papers was a review of results reported by two 
other studies, and was therefore excluded (15). The remaining 16 were a variety of 
non-randomized evaluation designs, and were evaluated in detail and given a quality 
rating using the 22 item TREND checklist (26). The two researchers (BC and RN) 
subsequently met to compare their ratings and an agreed consensus was reached. 
Analysis revealed that the average score for quality of methodology was 14.6 (range = 
11-17), with higher scores representative of an article meeting a greater number of 
methodological criteria (Table 1).  
 
Dosimetric data was collated from the articles regarding specific swallowing 
structures. These included of the base of tongue (BOT), pharyngeal constrictors (PC, 
as a single structure), as well as superior (SPC), middle (MPC) and inferior (IPC) 
pharyngeal constrictors, glottic/supraglottic larynx (GSL), upper esophageal sphincter 
(UES), and esophagus (ES). From this, only the most conservative evidence based 
dose constraints for these swallowing structures were collated from the literature 
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reviewed (Figure 2). For example, if dose constraints of V50 < 50Gy, V50 < 55Gy or 
V60 < 50Gy to the BOT were reported in separate studies, then V50 < 50Gy was 
included in the summary as the most conservative dose reported. 
 
 
Application of Known Dosimetric Parameters 
The second component of the current study aimed to determine whether those dose 
constraints identified in the literature as associated with swallowing outcomes post-
treatment were accurate at identifying swallowing, nutrition, and patient-rated 
functional impairment. As such, the dosimetric details of a homogenous cohort of 
patients who received 3D conformal AFRT-CB for T1-T3 oropharyngeal SCC were 
generated and applied to their swallowing, nutrition, and patient-rated outcomes.  
 
Participants 
The cohort included 12 participants taken from a group of 14 participants described 
previously in a prospective study examining functional outcomes (27). Demographic 
details are reported in Table 2, and maximum, mean and V40, V50, and V60 partial 
doses received by this cohort are reported in Table 3. Two participants from the 
original cohort were excluded as one participants’ radiotherapy planning data was 
unable to be restored (AF05), and for another the imaging was of insufficient quality 
to accurately delineate the target structures (AF04). Data analysis was, therefore, 
completed on the 12 participants who completed treatment and follow-up at 6 months 
post-treatment, and for whom accurate DVHs could be generated. No patient received 
chemotherapy or targeted therapies. All patients received their treatment at the Metro 
South Radiation Oncology Service in Brisbane, Australia. Ethics approval was 
obtained from the Princess Alexandra Hospital and The University of Queensland 
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Human Research and Ethics Committees, and all participants provided written 
consent prior to their involvement. 
 
Planned treatment and dose-volume histogram contouring 
Participants were treated with AFRT-CB of 66Gy in 35 fractions over 5 weeks using 
3D conformal planning techniques as per our institutional head and neck cancer 
treatment protocol. In the final two weeks of treatment, participants were given a 
second daily dose of 1.6Gy with at least 6 hours interfraction interval. Planning target 
volumes (PTV) were as follows: PTV1 to cover the primary and involved nodal 
regions and potential areas of local extension or lymphatic spread, (gross target 
volume [GTV] + 1.5cm plus potential areas of spread to nodes), and PTV2 to primary 
and involved node regions (GTV + 1.0cm). Contralateral nodes were included in the 
treatment field in patients with supraglottic and base of tongue disease or where there 
were pathological nodes in the ipsilateral neck (28). Unilateral treatment was given in 
patients with oropharyngeal disease where the ipsilateral neck was N0 (28).  
 
On completion of treatment, dose-volume histograms were generated for each 
participant to capture eight structures critical for swallowing in each participant. Two 
specialist radiation oncologists (SP and MP) supervised two junior medical staff (CB 
and RMR) in the accurate delineation of the target structures using CT imaging. From 
this information, DVHs of the BOT, PC, SPC, MPC, IPC, GSL, UES, and ES were 
generated using the Eclipse Treatment Planning System version 8.6 (Varian Medical 
Systems, Palo Alto, CA). The procedure for DVH generation was that described by 
the Trans-Tasman Radiation Oncology Group (TROG) in the 07.04 protocol (TROG 
registered number: A0031029V), and abided by anatomic boundaries described 
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previously (4, 12, 13, 16). Copies of the pictorial DVHs, as well as descriptive data 
regarding mean and maximum doses to each structure were provided to the principal 
investigator for analysis. DVHs were analysed for the following end points to 
determine: the percent volume to the BOT, PC, SPC, MPC, IPC, GSL, UES, and ES 
receiving partial doses of 40Gy (V40), 50Gy (V50), 60Gy (V60), the mean dose (MD), 
and the maximum dose (MaxD). The dosimetric data of each individual were then 
compared to the parameters in Figure 2 and coded as either 0 (structure received mean 
dose of less than that verified by the literature) or 1 (structure received mean dose of 
greater than that verified by the literature) for all eight swallowing structures. This 
identified which patients received doses to specific structures that met or exceeded 
suggested dose constraints to each swallowing structure. 
 
Outcome Measures 
The coded dose constraints (did or did not meet the criteria outlined in Figure 2) were 
then analysed against eleven end points measured at 6 months post-treatment in the 
AFRT-CB cohort to explain whether adherence to specific dosimetric parameters 
accurately identified who would be impaired/unimpaired post-treatment. These twelve 
endpoints included: 1) xerostomia and dysphagia toxicity grades 0-4 as per the 
Common Toxicity Criteria for Adverse Events version 3.0 (CTCAE v.3.0, (29); 2) full 
diet versus modified diet following following clinical swallow evaluation (CSE); 3) 
functional swallowing status using the Royal Brisbane Hospital Outcome Measure for 
Swallowing score (scores of 1-7 = impaired vs scores 8-10 = not impaired) 
(RBHOMS, (30) following CSE; 4) physiological swallowing impairment in 
pharyngeal contraction/bolus propulsion, laryngeal excursion, and clearance of 
pyriform sinus residue (0 = not impaired, 1 = impaired) using Subscale One of the 
 12 
New Zealand Index for Multidisciplinary Evaluation of Swallowing (NZIMES, (31) 
following videofluoroscopy (VFS); 5) presence of penetration or aspiration using the 
validated Penetration-Aspiration Scale (PAS, (32) using VFS; 6) general patient-rated 
function using the Functional Assessment of Cancer Therapy Additional Concerns for 
Head and Neck version 4 (FACT-H&N, (33), Head and Neck Specific score (score <36 
= impaired); 7) response FACT-H&N to question 7 “ I can swallow naturally and 
easily”(scores 3-4 = not impaired, scores 0-2 = impaired); 8) patient-rated swallowing 
function using the M. D. Anderson Dysphagia Inventory (MDADI, (34) global score 
(score <100 = impaired); 9) response to MDADI physical question 6 “swallowing 
takes me great effort” (scores 3-5 = not impaired, scored 1,2 = impaired); 10) global 
nutrition using the Patient-Generated Subjective Global Assessment (PG-SGA, (35) 
global score of A (not impaired) vs B or C (impaired); 11) loss of weight (LOW) of > 
10% between pre-treatment and 6 months post-treatment; and 12) requirement of 
alternative feeding at any time during or post-treatment. 
 
Statistical Analysis 
Receiver operating characteristic (ROC) analysis was used to determine which dose 
constraints accurately identified impairment in toxicity, dysphagia, patient-rated 
functional impact or nutrition endpoints at 6 months post-treatment in the AFRT-CB 
cohort. The data meeting the following two criteria were considered clinically 
important if: 1) the area under the curve (AUC) was > 0.75, and 2) the ROC curve 
assessed > 75% of the participants correctly (ie. met dose constraints and not 
impaired, plus exceeded dose constraints and impaired).  
 
RESULTS 
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Thirty-eight radiation dosimetric parameters were identified in the literature, and 25 
of those (66%) accurately identified the presence / absence of impairment in the 
AFRT-CB cohort at 6 months post-treatment. Table 4 and 5 report the ROC analyses 
meeting both clinically important criteria outlined above for toxicity/swallowing, and 
patient-rated functional impact/ nutritional end points, respectively.   
 
Analysis revealed specific partial doses to the BOT, SPC, and GSL correctly 
identified ongoing salivary or dysphagia toxicity at 6 months post-treatment. 
Additionally, a mean dose of greater than 51Gy to the SPC also identified ongoing 
salivary toxicity post-treatment. There were 13 dose constraints verified in the 
literature that correctly identified penetration and aspiration events (for fluids) in the 
current cohort (Table 4). Partial doses to the PC (V65), MPC (V65), IPC (V45-V60), 
GSL (V65), UES (V60, V65), and ES (V40) all correctly identified penetration and 
aspiration of fluids at 6 months post-treatment. Mean dose to the GSL of greater than 
48Gy, maximum dose to the UES of greater than 60Gy, and mean dose to the ES of 
greater than 17Gy also correctly identified penetration and aspiration of fluids at 6 
months. Other measures of physiological swallowing impairment (laryngeal excursion 
or clearance of pharyngeal residue) were correctly identified by partial doses to the 
BOT, PC, SPC, and IPC (Table 4). Additionally, partial doses to the BOT, SPC, and 
GSL correctly identified impairment in functional swallowing (RBHOMS) or the 
need for a modified diet at 6 months post-treatment (Table 4). 
 
A number of verified dose constraints also correctly identified some patient-rated 
functional impact and nutrition outcomes at 6 months post-treatment (Table 5). Only 
the mean (> 51Gy) and V40 partial (< 95%) doses to the SPC correctly identified 
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patient-rated functional impact for head and neck specific concerns on the FACT-
H&N, and responses to the statement “I can swallow naturally and easily”. All other 
dose constraints did not correctly identify any other patient-rated functional impact 
outcomes. Mean doses to the IPC (< 32Gy) and UES (<23Gy), as well as partial doses 
to the PC (V50), IPC (V40), and GSL (V35, V70) correctly identified the presence or 
absence of global nutritional impairment at 6 months post-treatment. A 10% loss of 
weight was correctly identified by partial doses to the BOT (V50) and SPC (V50) 
(Table 5). 
 
DISCUSSION 
The emerging evidence identifying radiation dosimetric factors which impact on 
swallowing and nutritional outcomes post-treatment is novel and innovative. The 
purpose of the current study was to highlight the accuracy of previously reported dose 
constraints in detailing a range of swallowing and nutritional outcomes at 6 months 
post-treatment, and has added to the emerging evidence in this area in two ways. 
Firstly, this study provides evidence that 66% of radiation dosimetric parameters 
verified by the literature accurately identify swallowing and nutritional outcomes at 6 
months post-treatment in a cohort of patients with oropharyngeal SCC treated with 
AFRT-CB, despite the methodological limitations of previous research. Secondly, this 
study presents seminal evidence for the impact of radiation dosimetric parameters on 
global nutritional status and percentage weight loss at 6 months post-treatment. 
 
The Current Evidence for Dosimetric Constraints and Swallowing Outcomes 
The current evidence base is small, generally retrospective in design, and has 
commonly utilised heterogenous head and neck cohorts, thus limiting the 
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generalizability of dose constraint recommendations into clinical populations with 
head and neck cancer. Furthermore, there is a very high degree of methodological 
variability between the tools used to determine dysphagia presence with assessment 
procedures varying from crude rating scales performed by medical staff (11, 13, 16, 17, 36) 
to detailed videofluroscopic assessments performed by speech pathologists (12, 22, 37). 
Similarly the variability between the outcome time points scored also varies 
dramatically. The majority of papers have compared the dosimetric parameters to 
swallowing outcomes at only one time point post-treatment, and this ranges from 4-8 
weeks (11) to more than seven years post-treatment (18). Some of the relationships have 
been established on outcomes seen as early as 3 months post-treatment (16, 20) (21) while 
most of the work has explored relationships to long term outcomes at either 6 months 
(20, 22, 36), or beyond (10, 12-14, 18-23, 25). Very few papers routinely scored outcomes at 
multiple time points post-treatment (20-22, 36). Furthermore the specific types of 
outcomes vary between studies with authors commenting on dose constraints to 
reduce dysphagia toxicity, aspiration, physiological impairment, stricture formation, 
patient-reported dysphagia, quality of life (QoL), and the need for alternative feeding. 
Hence it becomes obvious by examining this variability in methodology between 
studies that consistency in the recording and reporting of a core set of specific 
dysphagia and nutritional outcomes needs to be established.  
 
Application of Verified Dosimetric Parameters to an AFRT-CB Cohort 
The current study has found two thirds of published dose constraints accurately 
identified toxicity, swallowing, nutrition, and patient-rated function impairment at 6 
months post-treatment in the current AFRT-CB cohort. Those dose constraints 
included partial doses to the BOT, PC, SPC, MPS, IPC, GSL, UES, and ES, as well 
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as mean doses to the SPC, IPC, GSL, UES, and ES, and maximum dose to the UES. 
Conversely, several of the dose constraints previously reported did not accurately 
identify impairment in the AFRT-CB cohort at 6 months post-treatment, indicating 
further detailed and systematic study is required. 
 
Previously, a partial dose to the BOT of 50% receiving greater than 50Gy had been 
associated with aspiration (18), however the current study revealed this dose constraint 
also accurately identified impairment in salivary toxicity, laryngeal excursion, the 
need for a modified diet, and weight loss at 6 months post-treatment. It is not an 
unexpected result that the dose to the BOT, closely aligned with the parotid glands, is 
associated with long-term xerostomia. The impact of xerostomia on dietary 
modifications and subsequent weight loss has also been reported previously (38, 39), 
and it is not unanticipated that these impairments have co-occurred in the current 
cohort. The finding of impaired laryngeal excursion associated with BOT partial dose 
may reflect airway protection impairment. Adequate laryngeal excursion is necessary 
for epiglottic deflection and airway protection, and if impaired may result in 
penetration and aspiration as found by Jensen et al. (2007)(18). Similarly, the co-
occurrence of the need for a modified diet and weight loss both identified with a 
partial dose to the SPC of 90% receiving 50Gy. Feng et al. (2007)(16) suggested 
partial V50 dose to the SPC be reduced to 90% to avoid aspiration, however in the 
current cohort neither aspiration or penetration of fluids or solids was correctly 
identified with this dose constraint. 
 
Mean, maximum, and partial doses to the MPC, IPC, GSL, UES, and ES verified by 
the literature showed strong identification of penetration and aspiration events in the 
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current cohort. It appears that larger doses to these structures are a potential 
contributing factor to aspiration risk at 6 months post-treatment. With significant 
aspiration, often alternative feeding is recommended. Very few of the current cohort 
required short term NGT feeding, however Caudell et al. (12) found conservative 
partial doses to the IPC from V45-V60 were not associated with the need for alternative 
feeding. Thus, our results may confirm that the partial doses suggested by Caudell et 
al. (12) do accurately identify those at risk for alternative feeding as a result of 
penetration or aspiration. Only three of the suggested dose constraints to the GSL to 
reduce aspiration (MD <48Gy)(11) and alternative feeding (V65<23% and 
V70<4%)(12) correctly identified those who penetrated/aspirated at 6 months post-
treatment in the current cohort. UES partial doses receiving 60 and 65Gy did however 
accurately identify penetration and aspiration, whereas the literature has previously 
reported an association with stricture formation and patient-reported dysphagia not 
found in this study (20). The UES dose parameter previously associated with aspiration 
(V40<50%)(18), did not correctly identify it in the current cohort. Both esophageal (ES) 
doses previously associated with aspiration correctly identified penetration and 
aspiration in the current cohort (mean dose <17Gy, (23); V40<88%, (16)). 
 
Global nutritional outcome was correctly identified by mean and partial doses to the 
IPC, GSL, and UES. Global nutritional outcome has not previously been assessed in 
relation to dosimetric parameters, so this study provides the first evidence that 
parameters which have previously been associated with dysphagia toxicity (IPC mean 
dose <32Gy)(19), alternative feeding (IPC V40<65% and GSL V35<79%)(12), and 
aspiration (UES mean dose <23Gy)(23) also correctly identify those patients who will 
be at risk of malnutrition at 6 months post-treatment. In the general HNC population, 
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it could be hypothesised that dysphagia toxicity (grade 4 toxicity requiring alternative 
feeding), the need for alternative feeding, and aspiration would result in poor global 
nutritional status, so this finding confirms the clinical relevance of these dosimetric 
parameters.  
 
Although the evidence base is as yet small, current research has proposed a number 
of dosimetric constraints to key swallowing structures which may be influential in 
minimising the negative impact on swallowing, and potentially nutritional outcomes, 
following radiotherapy. Unfortunately, the number of significant methodological 
weaknesses in the current available literature must be acknowledged when 
interpreting the data at this time. Despite this, the application of the existing 
dosimetric parameters identified in the literature to our current cohort revealed that 
over two-thirds were consistent with the patient outcomes achieved. Future studies 
examining the predictive power of dosimetric factors need to include pre-treatment 
data, agreement on which swallowing OAR are contoured and how, and include 
outcome measure assessment which addresses the multifactorial nature of dysphagia 
and nutritional impairment, and uses validated measures. It is the hope that future 
rigorous, multidisciplinary studies will guide radiation oncologists and radiation 
therapists to optimize treatment plans and dose gradients to structures identified as 
associated with poor functional outcomes, allowing speech pathologists, dietitians 
and nurses involved in the rehabilitation of this population to better identify those 
patients at risk of developing dysphagia and/or nutritional compromise at 6 months 
post-treatment. Accordingly, this knowledge may guide alternative service delivery 
in the post-treatment phase to prevent functional impairment for those at risk.  
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TABLES 
 
Table 1. Consensus ratings given for each study reviewed using the TREND checklist 
 
Numbered TREND  
checklist items 
Alphabetical identifier of reviewed article 
A B C D E F G H I J K L M N O P 
1. Title and abstract                 
 Introduction  
2.      Background                 
 Methods  
3.      Participants                 
4.      Interventions                 
5.      Objectives                 
6.      Outcomes                 
7.      Sample size                 
8.      Assignment method                  
9.      Blinding (masking)                 
10.      Unit of analysis                 
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A = Anand et al., 2008, B = Bhide et al., 2009, C = Calgar et al., 2008, D = Caudell et 
al. 2010, E = Dirix, Abbeel, Vanstraelen, Hermans, & Nuyts, 2009, F = Dornfeld et 
al., 2007, G = Feng et al., 2007, H = Fua et al., 2007, I = Jensen, Lambertsen, & Grau, 
2007, J = Levendag et al., 2007, K = Li et al., 2009, L = Mittal et al., 2001, M = 
Sanguineti et al., 2011, N = Schwartz et al., 2010, O = Teguh, Levendag, Noever, et 
al., 2008, P = Teguh, Levendag, Sewnaik, et al., 2008 
11.      Statistical methods                 
 Results  
12.      Participant flow                 
13.      Recruitment                 
14.      Baseline data                 
15.      Baseline equivalence                 
16.      Numbers analysed                 
17.      Outcomes and Estimation                 
18.      Ancillary analyses                 
19.      Adverse events                 
 Discussion  
20.      Interpretation                 
21.      Generalizability                 
22.      Overall evidence                 
TOTAL QUALITY SCORE    /22 11 16 15 12 15 13 13 14 16 14 16 16 17 17 14 14 
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Table 2. Demographics of AFRT-CB participants for whom DVHs were generated 
 
Participant Age Sex* TNM† Classification Stage Smoking Alcohol Weight 
(kgs) 
AF01 82 M T1N0 left pharyngeal wall I Ex Current 70.3 
AF02 63 M T2N0 supraglottic II Current Current 77.8 
AF06 69 F T2N2b left tonsil  IV Ex N/A 73 
AF07 73 M T2N0 left tonsil II Ex Ex 61 
AF08 70 M T1N0 left tonsil  I Ex Current 106.7 
AF09 69 M T2N1 right tonsil  III Ex Current 65.8 
AF10 69 M T3N0 right supraglottic III Current Current 81 
AF12 59 M T2N0 right supraglottic II Ex Current 81 
AF13 59 M T1N2a right tonsil IV Never Current 83.4 
AF14 58 F T3N0 right tonsil III Current Current 59.5 
AF15 53 M T2N1 right tonsil III Never Current 142 
AF16 54 M T1N2a right tonsil IV Never Current 113 
*M = male, F = female. †T = T stage, N = N stage. 
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Table 3. Mean (Gy), maximum (Gy) and partial doses (%) to eight swallowing 
structures in the AFRT-CB cohort 
 
Site* MD† (SD) MaxD‡ (SD) % V40§ 
(range) 
% V50|| 
(range) 
% V60¶(range) 
BOT 57.2 (11.3) 68.9 (2.63) 88 (34-100) 77 (5-100) 56 (2-100) 
PC 47.6 (9.9) 68.7 (1.69) 72 (42-100) 60 (33-98) 43 (13-77) 
SPC 59.9 (6.2) 67.7 (2.8) 97 (65-100) 91 (53-100) 63 (0-100) 
MPC 55.5 (9.5) 65.7 (5.6) 88 (38-100) 73 (15-100) 50 (0-100) 
IPC 35.5 (19.1) 63.5 (7.7) 49 (6-100) 35 (0-100) 24 (0-100) 
GSL 41.3 (18.1) 64.6 (6.6) 60 (12-100) 47 (5-98) 31 (0-83) 
UES 19.2 (19.8) 36.4 (16.5) 19 (38.4) 15 (36.2) 7 (22.8) 
ES 11.5 (12.3) 31.5 (13.4) 8.3 (27.9) 3 (9.2) 0 (0) 
*BOT = base of tongue, PC = pharyngeal constrictors, SPC = superior pharyngeal 
constrictor, MPC = middle pharyngeal constrictor, IPC = inferior pharyngeal 
constrictor, GSL = glottic/supraglottic larynx, UES = upper esophageal sphincter, ES 
= esophagus. †MD = mean dose to structure. ‡MaxD = maximum dose to structure.  
§, ||, ¶ Percentage of structure receiving partial dose of 40Gy, 50Gy, and 60Gy, 
respectively. 
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Table 4. Clinically relevant ROC analysis of dose-constraints regarding toxicity and swallowing end points at 6 months post-AFRT-CB  
Site DVH 
parameter 
CTCAE 
Xerostomia 
CTCAE 
Dysphagia 
Pen/Asp 
Fluids 
Pen/Asp 
Solids 
Bolus 
Propulsion 
Larynx 
Excursion 
Clearance 
Residue* 
RBHOMS Modified 
Diet 
  AUC % AUC % AUC % AUC % AUC % AUC % AUC % AUC % AUC % 
BOT V50<50% 1.0 100 0.7 50 0.6 33 0.75 58 0.65 75 0.85 75 0.8 67 0.7 50 0.85 75 
PC V65<50% 0.61 42 0.5 58 0.83 92 0.67 67 0.67 50 0.78 67 0.83 75 0.72 75 0.56 50 
SPC Mean<51Gy 0.95 92 0.68 42 0.59 25 0.73 50 0.36 67 0.82 67 0.78 58 0.68 42 0.82 67 
 V40<95% 0.95 92 0.68 42 0.59 25 0.73 50 0.36 67 0.82 67 0.77 58 0.68 42 0.82 67 
 V50<90% 0.7 83 0.7 50 0.3 16 0.45 42 0.35 58 0.55 42 0.5 50 0.7 50 0.85 75 
 V55<80% 0.67 67 0.5 50 0.5 50 0.42 42 0.58 58 0.75 75 0.67 67 0.5 50 0.58 58 
 V65<33% 0.63 50 0.44 50 0.56 67 0.56 58 0.69 58 0.81 75 0.69 67 0.63 67 0.63 58 
MPC V65<75% 0.59 25 0.32 58 0.95 92 0.82 67 0.64 33 0.73 50 0.77 58 0.32 58 0.18 33 
IPC V45<58% 0.44 33 0.44 60 0.75 83 0.56 58 0.5 42 0.63 58 0.69 67 0.63 67 0.44 42 
 V50<48% 0.44 33 0.44 50 0.75 83 0.56 58 0.5 42 0.63 58 0.69 67 0.63 67 0.44 42 
 V55<21% 0.44 33 0.44 50 0.75 83 0.56 58 0.5 42 0.63 58 0.69 67 0.63 67 0.44 42 
 V60<12% 0.44 33 0.44 50 0.75 83 0.56 58 0.5 42 0.63 58 0.69 67 0.63 67 0.44 42 
 V65<2% 0.47 42 0.56 58 0.7 75 0.49 50 0.54 50 0.69 67 0.76 75 0.56 58 0.34 33 
GSL Mean<48Gy 0.44 33 0.44 50 0.75 83 0.56 42 0.5 42 0.63 58 0.69 67 0.63 67 0.44 42 
 V65<23% 0.44 33 0.44 50 0.75 83 0.56 58 0.5 42 0.63 58 0.69 67 0.63 67 0.44 42 
 V70<4% 0.59 25 0.86 75 0.41 75 0.27 50 0.64 33 0.73 50 0.77 58 0.86 75 0.73 50 
UES Max<60Gy 0.59 25 0.32 58 0.95 92 0.82 67 0.64 33 0.73 50 0.77 58 0.32 58 0.18 33 
 V60<78% 0.59 25 0.32 58 0.95 92 0.82 67 0.64 33 0.73 50 0.78 58 0.32 58 0.18 33 
 V65=0% 0.59 25 0.32 58 0.95 92 0.82 67 0.64 33 0.73 50 0.77 58 0.32 58 0.18 33 
ES Mean<17Gy 0.59 25 0.32 58 0.95 92 0.82 67 0.73 50 0.64 33 0.77 58 0.32 58 0.18 33 
 V40<88% 0.59 33 0.32 58 0.95 92 0.82 67 0.64 33 0.73 50 0.77 58 0.32 58 0.18 33 
Note. AUC = area under the curve where >0.75 considered significant, % refers to percent correctly identified (met dose constraint + not impaired plus exceeded dose constraint + 
impaired), bold refers to results which met both clinically important criteria (AUC>0.75 + % correctly identified >75%). *Refers to clearance of pyriform sinus residue 
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Table 5. Clinically relevant ROC analysis of dose-constraints regarding patient-rated function and nutrition end points at 6 months post-AFRT-CB  
Site* DVH 
parameter 
MDADI 
Global 
MDADI  
Physical Q6 
FACT H&N FACT H&N 
Q7 
NGT PG-SGA 
Global 
>10% loss of 
weight 
  AUC % AUC % ACU % AUC % AUC % AUC % AUC % 
BOT V50<50% 0.5 83 0.7 50 0.7 83 0.65 75 0.6 33 0.35 25 0.85 75 
PC V50<80% 0.5 25 0.28 42 0.61 42 0.67 50 0.39 58 0.78 83 0.33 33 
SPC Mean<51Gy 0.5 92 0.68 42 0.95 92 0.91 83 0.59 25 0.64 33 0.82 67 
 V40<95% 0.5 92 0.68 42 0.95 92 0.91 83 0.59 25 0.64 33 0.82 67 
 V50<90% 0.5 83 0.7 50 0.7 83 0.65 75 0.6 33 0.65 42 0.85 75 
IPC Mean<32Gy 0.5 50 0.33 33 0.67 67 0.42 42 0.67 67 0.75 75 0.58 58 
 V40<65% 0.5 42 0.21 25 0.64 58 0.37 33 0.53 58 0.80 83 0.51 50 
GSL V35<79% 0.5 42 0.21 25 0.64 58 0.37 33 0.53 58 0.80 83 0.51 50 
 V70<4% 0.5 8 0.32 58 0.59 25 0.64 33 0.41 75 0.91 83 0.73 50 
UES Mean<23Gy 0.5 25 0.28 42 0.61 42 0.44 33 0.61 75 0.78 83 0.33 33 
Note. AUC = area under the curve where >0.75 considered significant, % refers to percent correctly identified (met dose constraint + not impaired plus exceeded dose constraint + 
impaired), bold refers to results which met both clinically important criteria (AUC>0.75 + % correctly identified >75%). *Structures where no clinically relevant ROC analyses were 
found have not been included 
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Figure 1.   Example of cumulative dose volume histogram where each line represents the DVH of a specific structure (highlighted is the base of 
tongue [dashed line]. X axis refers to the Gray (Gy) dose delivered, and Y axis refers to the percentage (%) of the organ receiving the dose (Gy).
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BOT 
V50 <50% (I)  
PC 
Mean <64Gy (G) 
V40 < 90% (G) 
V50 < 80% (G) 
V60 < 70% (G) 
V65 < 50% (G) 
SPC 
Mean < 51Gy (J) 
V40 < 95% (G) 
V50 < 90% (G) 
V55 < 80% (P) 
V60 < 80% (G) 
V65 < 33% (D) 
MPC 
Mean < 48Gy (J) 
V65 < 75% (D) 
V70 < 53% (D) 
GSL 
Mean <48Gy (C) 
V35 < 79% (D) 
V40 < 50% (I) 
V45 < 45.5% (D) 
V50 < 21% (C) 
V55 < 32% (D) 
V60 < 24% (D) 
V65 < 23% (D) 
V70 < 4% (D) 
 
UES 
Mean < 23Gy (P) 
Max dose < 60Gy (K) 
V40 <50% (I) 
V60 <78% (K) 
V65 = 0% (K) 
ES 
Mean < 17Gy (P) 
V40 < 88% (G) 
Figure 2.   Dose parameters recorded for swallowing structures reported in the literature 
(study identified with alphabetical identifier as in Table 1) as relevant for swallowing 
outcomes, where BOT = base of tongue, PC = pharyngeal constrictors, GSL = 
glottic/supraglottic larynx, UES = upper esophageal sphincter, ES = esophagus, IPC = 
inferior pharyngeal constrictor, MPC = middle pharyngeal constrictor, and SPC = superior 
pharyngeal constrictor. 
IPC 
Mean < 32Gy (J) 
V40 < 65% (D) 
V45 < 58% (D) 
V50 < 48% (D) 
V55 < 21% (D) 
V60 < 12% (C) 
V65 < 2% (C) 
